SCHEMBL7965660

SCHEMBL7965660

CS(=O)(=O)OC[C@H](COCc1ccc(C#N)cc1)OS(C)(=O)=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.37
PLA2G10 O15496 2/20 0.37
PLA2G1B P04054 2/20 0.37
PLA2G2A P14555 2/20 0.37
PLA2G5 P39877 2/20 0.37
RAB9A P51151 2/20 0.36
CYP2A6 P11509 1/20 0.36
MAOB P27338 2/20 0.36
ALOX5 P09917 1/20 0.36
NPC1 O15118 2/20 0.35
CYP19A1 P11511 1/20 0.35
MAPT P10636 1/20 0.35
ADAMTS4 O75173 1/20 0.34
MMP13 P45452 1/20 0.34
LOXL2 Q9Y4K0 1/20 0.34
BCHE P06276 1/20 0.34
ACHE P22303 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
AR P10275 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7965664 1.00 TSHR (0.37) TSHRPLA2G10PLA2G1BPLA2G2APLA2G5
SCHEMBL11033646 0.82 TSHR (0.41) TSHRRAB9ANPC1MAPTSMN1; SMN2
SCHEMBL1979106 0.78 CYP2A6 (0.48) TSHRRAB9ACYP2A6MAOBNPC1
SCHEMBL5319833 0.77 CYP2A6 (0.42) TSHRRAB9ACYP2A6MAOBALOX5
SCHEMBL18186635 0.75 TSHR (0.47) TSHRRAB9ANPC1SMN1; SMN2AR
SCHEMBL5319832 0.73 CYP2A6 (0.41) TSHRRAB9ACYP2A6MAOBNPC1
SCHEMBL8456770 0.72 POLB (0.49) TSHRRAB9ACYP2A6MAOBCYP19A1
SCHEMBL2608936 0.72 CYP2A6 (0.48) TSHRRAB9ACYP2A6MAOBALOX5
SCHEMBL2057880 0.71 ALDH1A1 (0.43) TSHRALDH1A1
SCHEMBL9613931 0.71 KMT2A (0.43) TSHRNPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6274715-B1 SEMISYNTHETIC MACROLIDES, USEFUL IN BACTERIAL INFECTIONS TREATMENT AND PREVENTION, HAS LESS POTENTIAL FOR DEVELOPING RESISTANCE, IMPROVED OR MODIFIED PROFILES OF DESIRED GRAM-NEGATIVE ACTIVITY ABBOTT LABORATORIES 2001-08-14 US disclosed